[{"orgOrder":0,"company":"Legend Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"JNJ-4528","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Legend Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Legend Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"JNJ-4528","moa":"T Cell","graph1":"Oncology","graph2":"Phase III","graph3":"Legend Biotech","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Legend Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Ciltacabtagene autoleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Ciltacabtagene autoleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inravenoys infusion","sponsorNew":"Legend Biotech \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Ciltacabtagene autoleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Legend Biotech \/ Janssen Research & Development","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Janssen Research & Development"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Ciltacabtagene autoleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Centocor","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"LB1901","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Bortezomib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0.34999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.34999999999999998,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Morgan Stanley","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Morgan Stanley"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"LB1901","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Ciltacabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.65000000000000002,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Janssen","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Janssen"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.65000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Janssen Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Janssen Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"LB1908","moa":"Claudin 18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Janssen Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Janssen Pharmaceuticals"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"LB2102","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"LB2102","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":1.1100000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.1100000000000001,"dosageForm":"","sponsorNew":"Legend Biotech \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"LB2102","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":1.1100000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.1100000000000001,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"GenScript Biotech Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Legend Biotech \/ GenScript Biotech Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Legend Biotech \/ GenScript Biotech Corporation"}]
Find Clinical Drug Pipeline Developments & Deals by Legend Biotech
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
